Varmora Granito Ltd Q2 FY27 Results

In its first quarter as a listed company, Varmora Granito posted consolidated revenue of ₹399.0 Cr, up 8.8% YoY and 26.5% QoQ, with PAT attributable to owners of ₹45.3 Cr, up 175% YoY (PAT margin 11.4% vs 4.5% a year ago). EPS came in at ₹2.23 for the quarter (H1 FY27 EPS ₹2.87). Standalone revenue was ₹387.1 Cr with PAT of ₹23.3 Cr, up a more modest 37% YoY after absorbing a ₹17.9 Cr exceptional loss on the sale of its stake in subsidiary Simola Tiles LLP.

The gap between standalone and consolidated growth is explained almost entirely by that one transaction: at the standalone entity the stake sale registers as a loss, while at the Group level the same deal (deconsolidation of Simola Tiles LLP, now a 30%/29% associate rather than a subsidiary) nets to a small ₹0.6 Cr gain, so the drag essentially disappears on a consolidated basis. Excluding exceptional items on both sides, adjusted consolidated PAT growth is still ~202% YoY — confirming the jump is largely operating, not accounting. The operating margin story is the core of the quarter: EBITDA margin expanded to roughly 17.1% from ~5.7% a year ago and ~4.6% in Q1 FY27, helped by a drop in finance costs (₹6.8 Cr vs ₹9.7 Cr YoY). Against the pre-listing expectation range we flagged (revenue ~₹430–450 Cr, EBITDA margin 12–14%, PAT margin 3–4%), revenue came in below range while both margin metrics beat it comfortably — a miss on scale, a clear beat on profitability.

No management press release was available to cross-check against the company's own framing, and there is no formal prior guidance on record for this quarter. Post-listing analyst coverage remains thin — a web check found no Q2 FY27-specific consensus estimates, consistent with the pre-result read that research on the stock is still mostly pre-IPO in nature.

Varmora Granito listed in late September 2026 and now reports Q2 FY27—its debut quarter as a public company. The narrative is straightforward: capital raise of ₹708 Cr, deployment of ₹450 Cr capex over two years, and a drive toward ₹2,500 Cr revenue and ~10% PAT margins by FY29. Investors will parse three things: (1) how much capex has been deployed and what it signals for the run-rate going forward; (2) early evidence of the high-margin product mix shift (GVT now targeting 95% of sales, up sharply from 57% in FY23); and (3) cash and debt trends as the company invests to scale.

A strong Q2 would show: revenue in line with or ahead of the ₹430–450 Cr run-rate (implying solid traction post-IPO), EBITDA margins holding or expanding as GVT mix rises, and capex deployment proceeding on plan with no cash stress signals. A weak Q2 would flag slower revenue growth, margin compression from higher input costs or unfavorable mix, or cautious capex commentary that might imply delays to the FY29 roadmap.

Varmora is very early in its public life. FY26 (pre-IPO) posted ₹1,650+ Cr revenue with a 3.53% PAT margin. The FY29 target of ₹2,500 Cr implies 15% CAGR and a 3x margin expansion. That's achievable—the capex is meant to fund 800–900 Cr of new revenue and the GVT mix shift is a known margin lever. However, the company is in the investment phase: margin expansion will be gradual as capex ramps and new capacity comes online. Q2 should not show dramatic margin improvement; the wins will accrue later. The key is to see capex discipline and no warning signs on the revenue run-rate or input costs.

Board meeting announced for Oct 19 for Q2 approval. Trading window remained closed from Oct 1 onwards. No operational updates or insider trades flagged since listing. Block deals show steady activity: institutional/strategic buyers (SIDDHISURI FINVEST, GRT STRATEGIC VENTURES, LAXMI TRADE SOLUTIONS) and hedge fund selling (NK SECURITIES, KOMALAY INVESTRADE), consistent with post-IPO stabilization. No material pledges or regulatory red flags visible. The adoption of insider-trading code (Sep 29) is routine. Overall, no material surprises in the quarter; the company is executing its post-IPO transition quietly.

Varmora delivered 10.9% NPM in Q2—a solid recovery from Q1's fuel disruption, supported by 17% price hikes and a 7pp shift toward higher-margin GVT (82% mix). However, guidance is hedged: no specific FY27 revenue target (only 15% value + 10% volume ambition), no capex plan, and freight headwinds persist (18% export decline). The near-term outlook hinges on whether utilization reaches 80-85% and margins sustain above 10%, both execution-dependent in a contracting industry (10-11 Morbi plants closing).

Analysts pushed hard on sustainability of margins (10% margin at risk from cost inflation), capacity utilization path (Can Northeast reach 85%+ without cannibalization?), and competitive positioning (how do you compete with Kajaria's biofuel advantage in North?). Management held firm on all three, providing cost-benefit detail (freight premium, product mix uplift, government incentives), but deferred exact Northeast margin benefit to Q3 results. No analyst doubted recovery narrative, but two questioned export recovery timing and capex deferral sustainability.

Score 6/10. Clear on operational metrics (utilization, product mix, gas prices) and defensive on strategy (no capex, capital discipline). Limited forward visibility—deferred Northeast margin detail to Q3. Transparent on Q1 disruption and competitive position but sparse on long-term vision beyond FY27. Track record unavailable (first public call). Delivered 10.9% NPM, confirming pricing power on 17% hike and margin sustainability claims. Q1 fuel disruption exposure highlights operational vulnerability; recovery narrative credible but not exceptional vs. prior implied baseline.